Animal Models of Disease Core

疾病核心动物模型

• 批准号: 10091426
• 负责人: WENHAO XU
• 金额: $ 6.13万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-16 至 2022-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10091426
• 关键词: Adopted; Advisory Committees; Affect; Animal Cancer Model; Animal Disease Models; Animal Model; Animals; Archives; Area; Biological Sciences; Biometry; Breast; CRISPR/Cas technology; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Model; Charge; Collection; Colorectal; Communities; Consultations; Country; Cryopreservation; Cyclotrons; Databases; Derivation procedure; Disease; Drug resistance; Educational workshop; Endometrial; Epigenetic Process; Event; Evolution; Experimental Designs; Experimental Models; Foxes; Funding; Generations; Genetic; Genetic Engineering; Genetically Engineered Mouse; Genome engineering; Goals; Grant; Growth; Head and Neck Cancer; Human; Image; Imaging technology; Immune system; Infrastructure; Kidney; Knock-in Mouse; Knockout Mice; Laboratories; Leadership; Libraries; Lung; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Malignant neoplasm of urinary bladder; Measures; Microscopy; Modeling; Molecular; Mus; Mutation; National Center for Research Resources; Neoplasm Metastasis; Online Systems; Organ; Pathway interactions; Physiological; Positron-Emission Tomography; Price; Process; Property; Prostate; Research; Research Personnel; Resource Sharing; Services; Site; Specimen; Speed; Study models; System; Technology; Therapeutic; Time; Tissues; Training; Ultrasonography; United States National Institutes of Health; University of Virginia Cancer Center; Xenograft Model; biobank; biological research; cancer cell; clinically relevant; cohort; comparative; cost; data acquisition; equipment acquisition; fluorescence imaging; genome editing; imaging capabilities; imaging program; improved; in vivo monitoring; instrument; knockout gene; luminescence; medical schools; melanoma; member; model design; molecular imaging; mouse model; new technology; novel therapeutics; patient derived xenograft model; pre-clinical; research facility; service providers; spectroscopic imaging; technology development; tool; tumor; tumor growth; tumor microenvironment; tumor progression; tumor xenograft

ANIMAL MODEL OF DISEASE CORE – PROJECT SUMMARY/ABSTRACT The Animal Model of Disease Core (AMDC) is a comprehensive shared resource that has served UVA Cancer Center researchers' needs for more than two decades. Mice are one of the most widely used animal models for cancer. While cancer researchers have successfully studied the molecular and cellular properties of cancer cells propagated in culture, increasingly mouse models of cancer provide a more physiologically relevant opportunity to investigate the interplay of cancer cells, the tumor microenvironment, and the host immune system. Mouse models provide opportunities to study the evolution of cancer progression from first mutations to metastasis, and the unique opportunity to assess the genetic and epigenetic events correlated with acquisition of drug resistance. Following guidance from the UVACC leadership, the AMDC was formed by integrating two pre-existing shared resources: the Genetically Engineered Murine Model (GEMM) Core, and the Preclinical Tumor Assessment and Imaging Core, which consisted of the Tumor Xenograft Model (TXM) and Molecular Imagining Core (MIC) sections. This merger was conducted with the goal of better integrating cancer animal model creation, analysis and imaging. The AMDC integrates genome engineering, tumor xenografting, and imaging technologies to efficiently produce and analyze cancer animal models for UVA Cancer Center investigators. Since the last CCSG renewal, the AMDC has made great strides in novel technology development and state- of-art instrument acquisition. The AMDC swiftly adopted the Crispr-Cas9 technology for genome editing which enables cancer animal model generation at an unprecedented speed with significantly lowered cost. The AMDC also greatly expanded their library of patient derived xenograft (PDX) tumor models of ovarian cancer, head and neck cancers, and prostate and kidney GU cancers. The ultimate goal of these PDX efforts is to generate several lines of highly clinically relevant cancer models to be made widely available to the UVA community of cancer investigators. The AMDC has upgraded its PET imaging program with the addition of a cyclotron, which was funded by an NIH-NCRR high end instrument grant. In 2011, the cyclotron was installed in the Life Sciences Annex (built with funds from UVA SOM) adjoining the Snyder Building in the Fontaine Research Park. The AMDC is administered under ORCA, led by Dr. Jay W. Fox, the UVA Cancer Center Associate Director for Laboratory Infrastructure. AMDC staff routinely interact with other Cancer Center shared resources in particular the Biomolecular Analysis Facility, Biostatistics, Advanced Microscopy Facility, and Biorepository and Tissue Research Facilities. The interactions with other shared resource facilities on behalf of AMDC users help make the AMDC a one-stop service provider. Many of the AMDC users are UVA Cancer Center members who benefit from a co-pay that reduces their charges. The AMDC also is supported by the School of Medicine, which further lowers the cost for the Cancer Center users. The AMDC is reviewed annually by the Cancer Center leadership and the School of Medicine Research Advisory Committee to determine the level of subsidy required to maintain a revenue neutral core. The AMDC is competitive in pricing, rapid in service turnout time, and provides guarantees matching or exceeding the standards set up by comparative shared resources around the country.

疾病核心动物模型-项目总结/摘要 疾病核心动物模型（AMDC）是一个全面的共享资源， 癌症中心研究人员的需要超过二十年。小鼠是应用最广泛的动物之一 癌症的模型虽然癌症研究人员已经成功地研究了肿瘤的分子和细胞特性， 随着癌细胞在培养物中的增殖，越来越多的小鼠癌症模型提供了更生理学上的 研究癌细胞、肿瘤微环境和宿主之间相互作用的相关机会 免疫系统小鼠模型为研究癌症进展的演变提供了机会， 突变转移，以及评估相关的遗传和表观遗传事件的独特机会， 获得耐药性。 在UVACC领导层的指导下，AMDC通过整合两个先前存在的 共享资源：基因工程小鼠模型（GEMM）核心和临床前肿瘤 评估和成像核心，包括肿瘤异种移植模型（TXM）和分子成像 核心部分。此次合并的目的是更好地整合癌症动物模型 创建、分析和成像。AMDC整合了基因组工程，肿瘤异种移植和成像 技术，为UVA癌症中心研究人员有效地生产和分析癌症动物模型。 自上一次CCSG更新以来，AMDC在新技术开发和状态方面取得了长足进步， 最先进的仪器获取。AMDC迅速采用了Crispr-Cas9技术进行基因组编辑， 使癌症动物模型的产生以前所未有的速度和显著降低的成本成为可能。的 AMDC还极大地扩展了他们的卵巢癌患者来源的异种移植（PDX）肿瘤模型库， 头颈癌，前列腺癌和肾癌。这些PDX工作的最终目标是 产生几个高度临床相关的癌症模型线，以广泛提供给UVA 癌症研究者社区。AMDC已经升级了其PET成像程序，增加了一个 回旋加速器，这是由美国国立卫生研究院NCRR高端仪器赠款资助。2011年，回旋加速器安装在 在生命科学附件（由UVA SOM资助建造），毗邻方丹的斯奈德大楼 研究园区。 AMDC是在ORCA下管理的，由Jay W.福克斯，UVA癌症中心助理 实验室基础设施主任。AMDC工作人员定期与其他癌症中心共享资源互动 特别是生物分子分析设施、生物统计学、高级显微镜设施和生物储存库 组织研究机构。代表AMDC用户与其他共享资源设施的交互 帮助AMDC成为一站式服务提供商。 许多AMDC用户都是UVA癌症中心的成员，他们受益于降低 他们的指控AMDC还得到了医学院的支持，这进一步降低了 癌症中心用户AMDC每年由癌症中心领导层和医学院审查。 药物研究咨询委员会决定维持收入所需的资助水平 中性核AMDC在价格上具有竞争力，服务交付时间迅速，并提供保证 达到或超过全国范围内比较共享资源所设定的标准。